| Vaccine Type | Components | Immune Response Profile (Th1/Th2/Th17) | Duration of Protection | Advantages | Limitations | Current Use |
|---|---|---|---|---|---|---|
| Whole-cell pertussis vaccine (wP/DTwP) | Killed whole *B. pertussis* cells, typically combined with diphtheria and tetanus toxoids | Stronger Th1/Th17-polarized cellular immunity; more balanced humoral/cellular response than acellular vaccines (pqac-00000018, pqac-00000020, pqac-00000023, pqac-00000029) | Longer than acellular vaccines; cited protection roughly 7-20 years after natural infection and generally more durable priming than aP (pqac-00000018, pqac-00000024) | Better durability; stronger mucosal-relevant cellular priming; associated with lower later pertussis risk when used for priming (pqac-00000018, pqac-00000029, pqac-00000032) | Higher reactogenicity, historically including fever and neurologic adverse reactions; less acceptable in many high-income settings (pqac-00000017, pqac-00000023) | Still widely used in many low- and middle-income countries in DTwP-containing EPI schedules (pqac-00000021, pqac-00000024) |
| Acellular pertussis vaccine (aP/DTaP) | Purified 1-5 antigens, commonly PT, FHA, PRN, FIM2/FIM3, combined with diphtheria/tetanus toxoids | More Th2-skewed, especially with alum adjuvant; less effective induction of Th1/Th17 and mucosal memory than wP (pqac-00000017, pqac-00000018, pqac-00000019, pqac-00000023, pqac-00000039) | Waning immunity is substantial; efficacy cited around 85% after 6 doses with decline of ~11.7% annually; protection often 4-12 years (pqac-00000018, pqac-00000021) | Lower reactogenicity; safer and better tolerated; standard product in many high-income countries (pqac-00000018, pqac-00000023, pqac-00000024) | Rapid waning; does not reliably prevent nasal colonization or transmission; may contribute to vaccine-driven selection of antigen-deficient strains such as PRN-negative isolates (pqac-00000017, pqac-00000019, pqac-00000039, pqac-00000044) | Routine infant immunization in many high-income countries, usually as DTaP-containing combination vaccines (pqac-00000018, pqac-00000021, pqac-00000024) |
| Tdap booster | Reduced-antigen acellular booster containing tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis antigens | Booster humoral response but still based on acellular platform; protection remains less durable than wP-primed immunity (pqac-00000018, pqac-00000021) | Initial effectiveness about 85%, decreasing by ~12% annually in cited review evidence (pqac-00000021) | Useful for adolescent/adult boosting and maternal immunization; reduces infant risk via transplacental antibody transfer during pregnancy (pqac-00000021, pqac-00000047, pqac-00000051) | Waning protection; does not fully solve transmission or colonization; repeated boosting may be needed (pqac-00000021, pqac-00000039) | Used for childhood/adolescent boosters, adult boosters in some countries, and maternal vaccination in pregnancy (pqac-00000018, pqac-00000021, pqac-00000047) |
| OMV-based vaccines | Outer membrane vesicles containing native immunogenic structures including toxins, adhesins, and LPS/LOS-associated components | More balanced response than aP; induces innate plus adaptive immunity and broader IgG subclass patterns resembling wP more than aP (pqac-00000019, pqac-00000020, pqac-00000022) | Not yet established in humans; promising preclinical durability and protection in animal/preclinical studies (pqac-00000019, pqac-00000020) | Native antigen presentation; potentially equivalent bacterial protection with milder inflammatory responses than wP; promising next-generation platform (pqac-00000019, pqac-00000020) | Manufacturing standardization challenges related to strain choice, culture conditions, extraction, and purification; no established routine human use yet (pqac-00000019, pqac-00000020) | Experimental/preclinical development; not standard of care (pqac-00000019, pqac-00000020, pqac-00000022) |
| BPZE1 live attenuated vaccine | Live attenuated *B. pertussis* strain with inactivated major toxins including PT, TCT, and DNT | Induces IgG, IgA, memory B cells, and a Th1-type response; broader antibody specificity and mucosal-relevant immunity than standard aP vaccines (pqac-00000017, pqac-00000057) | Human duration still under study; preclinical single-dose protection reported in mice (pqac-00000057) | Nasal administration; potential to induce mucosal immunity and improve protection against infection/transmission, not just disease (pqac-00000017, pqac-00000057) | Investigational; efficacy, long-term durability, and broader deployment remain under evaluation (pqac-00000017, pqac-00000057) | In clinical development; phase 2b cited with controlled human infection work (NCT05461131) (pqac-00000057) |
| Intranasal mucosal vaccines | Intranasally delivered aP formulations, live attenuated candidates, or other adjuvanted mucosal platforms | Designed to induce local IgA, IL-17, Th1/Th17 responses, and tissue-resident memory CD4+ T cells in respiratory mucosa (pqac-00000017, pqac-00000029, pqac-00000030, pqac-00000032, pqac-00000035) | Human durability not yet fully defined; concept aims for stronger and more persistent anti-colonization immunity than injectable aP (pqac-00000017, pqac-00000029, pqac-00000032) | Best aligned with infection site; may prevent nasal colonization and transmission while also protecting against disease (pqac-00000017, pqac-00000026, pqac-00000029) | Mostly investigational; formulation, adjuvant, and safety optimization remain active research areas (pqac-00000017, pqac-00000022, pqac-00000032) | Experimental/clinical development; not yet routine public-health use (pqac-00000017, pqac-00000022, pqac-00000032) |


*Table: This table compares established and emerging pertussis vaccine platforms across composition, immune profile, durability, strengths, and limitations. It is useful for understanding why current acellular vaccines reduce severe disease yet incompletely prevent transmission, and why mucosal and live-attenuated approaches are being pursued.*